Author:
Puzanov I., ,Diab A.,Abdallah K.,Bingham C. O.,Brogdon C.,Dadu R.,Hamad L.,Kim S.,Lacouture M. E.,LeBoeuf N. R.,Lenihan D.,Onofrei C.,Shannon V.,Sharma R.,Silk A. W.,Skondra D.,Suarez-Almazor M. E.,Wang Y.,Wiley K.,Kaufman H. L.,Ernstoff M. S.
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Reference104 articles.
1. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235–47.
2. Papaioannou NE, et al. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261.
3. Administration, U.S.F.a.D. Drugs@FDA: FDA approved drug products. 2017 June 19th, 2017]; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm .
4. Company, B.-M.S. Ipilimumab (Yervoy) Highlights of Prescribing Information. 2017 3/2017 [cited 2017 June 19th, 2017]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf .
5. Company, B.-M.S. Nivolumab (Opdivo) Highlights of Prescribing Information. 2017 4/2017 [cited 2017 June 19th, 2017]; Available from: https://packageinserts.bms.com/pi/pi_opdivo.pdf .